Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center

Prostate Cancer and Prostatic Diseases volume 5, pages 152–158 (2002)Cite this article

Abstract

The use of prostate specific antigen (PSA) in the 1990s has brought on a stage migration of prostate cancer. Despite that, many men have still presented with metastatic prostate cancer in the past decade. The use of primary hormone therapy in the PSA era at a tertiary care Army Medical Center is studied in this paper. Charts were reviewed of 135 men who were diagnosed with metastatic prostate cancer and treated with hormone therapy as a primary treatment between 1989 and 1995. Statistical analysis was used to determine significant predictor variables on the time to disease progression. In univariate analysis clinical stage, pretreatment alkaline phosphatase and nadir PSA values were significant predictors of time to progression. Race and type of treatment were not. In multivariate analysis the relative risk of progression was 3.2 for patients with an alkaline phosphatase >252 and 16.5 for patients with a nadir >2.0. This study supports the argument that racial disparities in prostate cancer outcomes are due to access to care. Furthermore, the survival rate for patients with D-2 disease is better than in the pre PSA studies. Clinical stage, pretreatment alkaline phosphatase and PSA nadir can be used to predict response for those men presenting with metastatic prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 4
Figure 3

Similar content being viewed by others

References

  1. Greenlee RT, Hill-Harmon MM, Thun M . Cancer statistics 2001 CA Cancer J Clin 51: 15–37

    Article  CAS  Google Scholar 

  2. Smith RA et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers CA Cancer J Clin 2001 51: 38–75

    Article  CAS  Google Scholar 

  3. Moul JW . Treatment options for prostate cancer: Part I-stage, grade, PSA and changes in the 1990s Am J Manag Care 1998 4: 1031–1036

    Google Scholar 

  4. Moul JW . Contemporary hormonal management of advanced prostate cancer Oncology 1998 12: 499–505

    CAS  PubMed  Google Scholar 

  5. Hussain A, Dawson N . Management of advanced/metastatic prostate cancer: 2000 update Oncology 2000 14: 1677–1684

    CAS  PubMed  Google Scholar 

  6. Optenberg SA et al. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system JAMA 1995 274: 1599

    Article  CAS  Google Scholar 

  7. Thompson I et al. African-American ethnic background is an independent and negative predictor of survival in metastatic prostate cancer J Urol 2000 163: (Suppl 4) 56 (abstract no. 242)

    Google Scholar 

  8. Smith JA et al. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate J Urol 1997 157: 1329

    Article  Google Scholar 

  9. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients Lancet 1995 346: 265

  10. Pienta KJ et al. Effect of age and race on the survival of men with prostate cancer in the metropolitan Detroit tri-county area, 1973 to 1987 Urology 1995 45: 93

    Article  CAS  Google Scholar 

  11. Crawford E et al. A controlled trial of leuprolide with and without flutamide in prostate cancer New Engl J Med 1989 321: 419–424

    Article  CAS  Google Scholar 

  12. Denis LJ et al. Maximal androgen blockage: final analysis of EORETC phase III trial 30853. EOERTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center Eur Urol 1998 33: 144–151

    Article  CAS  Google Scholar 

  13. Betanga C et al. Efficacy of the combination of nilutamide plus orchiectomy in patients with metastatic prostate cancer: a meta-analysis of seven randomized, double-blind trials (1056 patients) Br J Urol 1994 73: 396–402

    Article  Google Scholar 

  14. Janknegt RA, Abbou CC, Bartoletti R, Berstein-Hahn L . Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multi-national double-blind randomized trial J Urol 1993 149: 77–83

    Article  CAS  Google Scholar 

  15. Eisenberger MA et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer New Engl J Med 1998 339: 1036–1042

    Article  CAS  Google Scholar 

  16. Caubet JF et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens Urology 1997 49: 71

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are supported by a grant from the Center for Prostate Disease Research, a program of the Henry M Jackson Foundation for the Advancement of Military Medicine (Rockville, MD, USA), funded by the US Army Medical Research and Materiel Command.

Author information

Authors and Affiliations

  1. Department of Surgery, Urology Service, Walter Reed Army Medical Center, Washington, DC, USA

    S G Koff, J J Bauer, D G McLeod & J W Moul

  2. Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of Health Sciences, Bethesda, Maryland, USA

    S G Koff, R R Connelly, J J Bauer, D G McLeod & J W Moul

Authors
  1. S G Koff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R R Connelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J J Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D G McLeod
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J W Moul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J W Moul.

Additional information

The opinions and assertions contained herein are the private views of the authors and are not to be construed as reflecting the views of the US Army or the Department of Defense.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koff, S., Connelly, R., Bauer, J. et al. Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center. Prostate Cancer Prostatic Dis 5, 152–158 (2002). https://doi.org/10.1038/sj.pcan.4500551

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500551

Keywords

This article is cited by

Search

Advanced search

Quick links